deltatrials

Acute myeloid leukemia Trials in Braunschweig, Germany

Conditions / Acute myeloid leukemia / Braunschweig, Germany

Research into Acute myeloid leukemia spans multiple therapeutic approaches and trial phases.

19 total trials for this combination

Showing top 10 of 19 trials

Trials

NCT ID Title Status Phase
NCT02785900 Vadastuximab Talirine (SGN-CD33A; 33A) Combined With Azacitidine or Decitabine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia TERMINATED PHASE3
NCT04093570 A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose) ENROLLING_BY_INVITATION PHASE2
NCT02668653 Quizartinib With Standard of Care Chemotherapy and as Continuation Therapy in Patients With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (AML) COMPLETED PHASE3
NCT04256317 A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study) RECRUITING PHASE2/PHASE3
NCT02920008 Phase 3 Randomized, Open-Label Study of Guadecitabine vs Treatment Choice in Previously Treated Acute Myeloid Leukemia COMPLETED PHASE3
NCT05079230 Study of Magrolimab Versus Placebo in Combination With Venetoclax and Azacitidine in Participants With Acute Myeloid Leukemia TERMINATED PHASE3
NCT07075016 Ivosidenib and Azacitidine With or Without Venetoclax in Adult Patients With Newly Diagnosed IDH1-Mutated AML or MDS/AML Considered Ineligible for Intensive Chemotherapy RECRUITING PHASE3
NCT03306264 Study of ASTX727 vs IV Decitabine in Participants With MDS, CMML, and AML COMPLETED PHASE3
NCT02719574 Open-label Study of FT-2102 With or Without Azacitidine or Cytarabine in Patients With AML or MDS With an IDH1 Mutation COMPLETED PHASE1/PHASE2
NCT04778397 Study of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Patients With TP53 Mutant Acute Myeloid Leukemia That Have Not Been Treated TERMINATED PHASE3

Related Pages